摘要
目的观察曲美他嗪对收缩性心力衰竭(CHF)患者心功能的影响。方法将60例收缩性心力衰竭患者随机分为对照组和治疗组,各30例。对照组给予血管紧张素转换酶抑制剂或血管紧张素Ⅱ受体拮抗剂、β受体阻滞剂、醛固酮受体拮抗剂、洋地黄等治疗;治疗组在此基础上加用曲美他嗪20mg,每天3次,连续用药6个月。服药前后记录血脑利钠肽(BNP)、C-反应蛋白(CRP)、左室射血分数(LVEF)、心功能NYHA分级、6min步行距离(6MWT)。结果 2组患者治疗后CRP、BNP水平均较治疗前明显下降,且治疗组低于对照组,差异均有统计学意义(P<0.05)。2组患者治疗后心功能NYHA分级、LVEF、6MWT较治疗前均有改善,且治疗组优于对照组,差异有统计学意义(P<0.05)。结论曲美他嗪治疗收缩性心力衰竭安全有效,能更明显改善患者的临床症状和心功能指标。
Objective To observe the clinical effects of trimetazidine on the treatment of heart function of congestive heart failure（CHF）.Methods 60 patients were randomly divided into treatment group and control group,all 30 cases.The control group was treated with angiotensin converting enzyme inhibitor（ACEI）or angiotensin II receptor blocker,β-blocker,aldosterone receptor antagonist and digitalis,etc.Besides the same treatment as the control group,trimetazidine was added to treatment group,20mg,three times a day.All the patients were treated for 6 months.Before and after treatment,the plasma brain natriuretic peptides（BNP）,C-reactive Protein（CRP）,left ventricular ejection fraction（LVEF）,cardiac function classification（NYHA） and the six-minute walk test（6MWT） were observed.Results After treatment,the CRP and BNP levels of two groups were decreased,and the treatment group than the control group,the differences were statistically significant（P0.05）.After treatment,the NYHA classification of cardiac function,LVEF,6MWT were improved,and the treatment group than the control group,the difference were statistically significant（P0.05）.Conclusion Combined use of trimetazidine is safe and effective in CHF,it can markedly improve the clinical symptoms and heart function indexes.
出处
《临床合理用药杂志》
2010年第16期7-8,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
曲美他嗪
心力衰竭
收缩性
心功能
Trimetazidine
Heart failure
congestive
Heart function
